ATE141047T1 - Verlängerte wirkstoffabgabe von kleinen, wasserlöslichen molekülen - Google Patents

Verlängerte wirkstoffabgabe von kleinen, wasserlöslichen molekülen

Info

Publication number
ATE141047T1
ATE141047T1 AT90116768T AT90116768T ATE141047T1 AT E141047 T1 ATE141047 T1 AT E141047T1 AT 90116768 T AT90116768 T AT 90116768T AT 90116768 T AT90116768 T AT 90116768T AT E141047 T1 ATE141047 T1 AT E141047T1
Authority
AT
Austria
Prior art keywords
fluid
biologically active
polymeric matrix
water
molecules
Prior art date
Application number
AT90116768T
Other languages
English (en)
Inventor
Bernhard A Dr Sabel
Andrew Freese
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE141047T1 publication Critical patent/ATE141047T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90116768T 1989-09-14 1990-08-31 Verlängerte wirkstoffabgabe von kleinen, wasserlöslichen molekülen ATE141047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/407,418 US5114719A (en) 1987-04-29 1989-09-14 Extended drug delivery of small, water-soluble molecules

Publications (1)

Publication Number Publication Date
ATE141047T1 true ATE141047T1 (de) 1996-08-15

Family

ID=23612002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90116768T ATE141047T1 (de) 1989-09-14 1990-08-31 Verlängerte wirkstoffabgabe von kleinen, wasserlöslichen molekülen

Country Status (6)

Country Link
US (1) US5114719A (de)
EP (1) EP0417572B1 (de)
AT (1) ATE141047T1 (de)
DE (1) DE69028011T2 (de)
DK (1) DK0417572T3 (de)
ES (1) ES2093625T3 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
ES2150427T3 (es) * 1992-06-02 2000-12-01 Bard Inc C R Procedimiento y dispositivo de implante para el suministro de farmacos a largo plazo.
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5383873A (en) * 1992-12-09 1995-01-24 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US5751629A (en) * 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6214901B1 (en) * 1998-04-27 2001-04-10 Surmodics, Inc. Bioactive agent release coating
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
AU2001281304B2 (en) 2000-08-15 2006-05-25 Surmodics, Inc. Medicament incorporation matrix
EP1343548B1 (de) * 2000-11-28 2012-03-28 Boston Scientific Limited Vorrichtung und verfahren zur abgabe von therapeutika
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20030232087A1 (en) * 2002-06-18 2003-12-18 Lawin Laurie R. Bioactive agent release coating with aromatic poly(meth)acrylates
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US8105652B2 (en) * 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
AU2004237774B2 (en) * 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
US20100285087A1 (en) * 2003-05-16 2010-11-11 The University Of Texas Single phenothiazine enantiomers as agents for the prevention of bone loss
US8637503B2 (en) * 2003-05-16 2014-01-28 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
ZA200509063B (en) * 2003-05-30 2007-03-28 Titan Pharmaceuticals Inc Impiantable polymeric device for sustained release of nalmefene
US20060083772A1 (en) * 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
US7541048B2 (en) * 2004-04-06 2009-06-02 Surmodics, Inc. Coating compositions for bioactive agents
EP1781264B1 (de) * 2004-08-04 2013-07-24 Evonik Corporation Verfahren zur herstellung von abgabevorrichtungen und damit erhaltene vorrichtungen
EP2162283B1 (de) 2007-06-14 2015-08-12 Massachusetts Institute of Technology Selbstaufbauende filme für protein- und arzneimittelabgabeanwendungen
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
WO2010021973A2 (en) * 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
SG184059A1 (en) 2010-03-16 2012-10-30 Titan Pharmaceuticals Inc Heterogeneous implantable devices for drug delivery
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US10278927B2 (en) 2012-04-23 2019-05-07 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
JP6549482B2 (ja) 2012-06-01 2019-07-24 サーモディクス,インコーポレイテッド バルーンカテーテルをコーティングするための装置および方法
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
US9956323B2 (en) 2014-12-18 2018-05-01 Cook Medical Technologies Llc Medical devices for local bioactive delivery
CN105380909B (zh) * 2015-12-25 2018-07-17 武汉回盛生物科技股份有限公司 一种氟苯尼考可溶性粉及其制备方法
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
AU2017263253B2 (en) 2016-05-12 2022-04-14 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11419947B2 (en) 2017-10-30 2022-08-23 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
US20220002564A1 (en) * 2018-10-17 2022-01-06 Dow Global Technologies Llc A coating composition, a coated fabric, a method of making a coated fabric, and an article made from the coated fabric
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
EP3975841A1 (de) 2019-05-30 2022-04-06 Massachusetts Institute of Technology Peptid-nukleinsäurefunktionalisierte hydrogelmikronadeln zur probenahme und detektion von nukleinsäuren in interstitieller flüssigkeit
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices
EP4352226A1 (de) 2021-06-07 2024-04-17 Yale University Peptidnukleinsäuren zur räumlich-zeitlichen steuerung der crispr-cas-bindung
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
US20250032644A1 (en) 2023-07-25 2025-01-30 Massachusetts Institute Of Technology Compositions and methods for treating fan1 associated trinucleotide repeat expansion disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US153896A (en) * 1874-08-11 Improvement in argand-burners
DE1215291B (de) * 1961-04-07 1966-04-28 Blendax Werke Schneider Co Einrichtung an in Laengsrichtung geteilten, aufklappbaren Giessformen fuer wachsaehnliche Massen
US3518150A (en) * 1966-09-27 1970-06-30 Philip G Patch Devices for bonding thermoplastic filaments
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4278087A (en) * 1980-04-28 1981-07-14 Alza Corporation Device with integrated operations for controlling release of agent
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS57130914A (en) * 1981-02-04 1982-08-13 Agency Of Ind Science & Technol Prolongation of activity retention
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
NL8401912A (nl) * 1984-06-15 1986-01-02 Tno Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan.
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
EP0226061B1 (de) * 1985-12-17 1994-02-16 United States Surgical Corporation Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon
US4761289A (en) * 1986-10-10 1988-08-02 International Minerals & Chemical Corp. Sustained release implant and method for preparing same
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
DE19975054I2 (de) * 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat

Also Published As

Publication number Publication date
DK0417572T3 (da) 1996-09-02
EP0417572A3 (en) 1991-06-12
EP0417572B1 (de) 1996-08-07
US5114719A (en) 1992-05-19
DE69028011D1 (de) 1996-09-12
ES2093625T3 (es) 1997-01-01
EP0417572A2 (de) 1991-03-20
DE69028011T2 (de) 1997-01-23

Similar Documents

Publication Publication Date Title
ATE141047T1 (de) Verlängerte wirkstoffabgabe von kleinen, wasserlöslichen molekülen
NO171004C (no) Fremgangsmaate for fremstilling av en utleveringsanordningsom i naervaer av en opploesningsvaeske frigir en biologisk aktiv bestanddel ved en i praksis konstant hastighet under en utvidet tidsperiode
IL78895A (en) Controlled release implant composition for macromolecular drugs
ATE135906T1 (de) Tabletten mit gesteuerter wirkstoffabgabe
CA2029383A1 (en) Swelling modulated polymeric drug delivery device
ATE114242T1 (de) Auf quervernetzte polymere aufgebrachte und mit polymerfilmen beschichtete therapeutische zusammensetzungen mit kontrollierter freisetzung von medikamenten und deren herstellungsverfahren.
ATE87470T1 (de) Biologisch abbaubare hydrogel-matrices zur kontrollierten freisetzung pharmakologisch aktiver wirkstoffe.
EP0179023A3 (en) With micro-organisms degradable polypeptide, and its use for the progressive release of medicaments
EP0123585A3 (en) Transdermal drug form
MY102859A (en) A composition for the control of insects.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
DE3766308D1 (de) Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.
ES2116308T3 (es) Dispositivo implantable a base de un material polimero, que contiene principios activos farmaceuticos, asi como procedimiento para su produccion.
EP0325086A3 (de) Verfahren zur Herstellung von therapeutischen Systemen mit gesteuerter Freigabe des Wirkstoffes
DE58909724D1 (de) Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe
US4931281A (en) Laminar structure for administering a chemical at a controlled release rate
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
DE69212135D1 (de) Herstellung von homogenen Hydrogel-Copolymeren
DE3879545T1 (de)
ES2073454T3 (es) Soporte para moleculas biologicamente activas o a su vez biologicamente activo, su procedimiento de preparacion y su aplicacion en biologia.
DE3772954D1 (de) Arzneimittel mit verzoegerter wirkstoffabgabe.
NL7901919A (en) Polymer compsn. contg. physiologically active cpd. - with controlled release mixt., prepd. by polymerising monomers with radiation at below room temp. (NL 11.9.79)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time